21/11/2023 02:44 PM

KUALA LUMPUR, Nov 21 (Bernama) -- Nanjing IASO Biotechnology Co Ltd (IASO Bio) made its debut at the Sixth China International Import Expo (CIIE) with FUCASO, the world's first fully-human chimeric antigen receptor T-cell (CAR-T).

In a statement, the company said it has also entered into a strategic partnership with several international medical institutions, bringing hope for cure to multiple myeloma (MM) patients worldwide.

The China National Medical Products Administration (NMPA) approved the marketing of FUCASO’s Equecabtagene Autoleucel Injection for the treatment of adult patients with relapsed or refractory multiple myeloma (r/rMM), on June 30.

Meanwhile, the injection has received the Orphan Drug Designation, as well as the Regenerative Medicine Advanced Therapy and Fast Track Designations from the United States (US) Food and Drug Administration, and has been approved for clinical trials in the US.

A single infusion of FUCASO can lead to lasting and deep remission with a favourable safety profile in patients with r/rMM who have failed multiple lines of therapy.

Due to its unique design, FUCASO, as a fully-human CAR-T therapy, is able to persist in patients for a longer period of time, offering hope for overcoming the challenging problem of relapsed MM.

FUCASO has attracted patients from numerous countries around the world to seek treatment in Chinese hospitals in just four months since its approval for marketing in China.

These hospitals have a world-leading level of full-process management in CAR-T therapy, in addition to the cost of treatment with FUCASO in China is significantly lower than that of similar products in Europe and America, which has benefitted more patients worldwide.


BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires;; BERNAMA TV on Astro 502, unifi TV 631 and MYTV 121 IFLIX channels and BERNAMA Radio on FM93.9 (Klang Valley), FM107.5 (Johor Bahru), FM107.9 (Kota Kinabalu) and FM100.9 (Kuching) frequencies.

Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter :, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial

© 2024 BERNAMA   • Disclaimer   • Privacy Policy   • Security Policy